Abstract: The enzymatic hydrolysis of food proteins can produce uric acid-lowering peptides. Hyperuricemia can cause a series of metabolic syndromes such as gout, cardiovascular disease, kidney disease and diabetes, seriously threatening human health. Numerous uric acid-lowering drugs have toxic and side effects clinically. Therefore, it is of practical significance to develop more safe and effective uric acid-lowering peptides. This article summarizes the pathogenesis of hyperuricemia, the methods commonly used to establish animal models of hyperuricemia, the structure-activity relationship between uric acid-lowering peptides and xanthine oxidase, and the current status of research on the in vivo activity of uric acid-lowering peptides. Finally, we conclude with an outlook on future research directions. This article aims to provide theoretical support for the development and research of uric acid-lowering peptides.

Key words: uric acid-lowering peptides; hyperuricemia; animal models; mechanism of action